Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 196 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR New targeted treatment for early breast cancer could reduce risk of... July 21, 2022 Longitudinal Molecular Profiling of CTCs Captures New Insights in mRCC June 1, 2022 EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Vipivotide Tetraxetan October 19, 2022 ‘Dance Moms’ Star Abby Lee Miller Opens Up About Her Cancer... April 19, 2019 Load more HOT NEWS Five Questions with…Debra. Man Who Lost His Mother to Breast Cancer Opens Resource Center... Shorter Course of Radiation Is Effective, Safe for Some with Early-Stage... Witness the Moment of Absolute Triumph as Baltimore Woman Is Finally...
